Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1 Clinical Study in Healthy Participants
Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd.
Summary
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-41012 in Healthy Participants
Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-41012 in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2026-05-15
Completion Date
2028-01-31
Last Updated
2026-05-13
Healthy Volunteers
Yes
Conditions
Interventions
BW-40202 injection or Placebo
BW-40202 injection or Placebo dosage form is solution for injection and route of administration is subcutaneous injection
BW-40202 injection or Placebo
BW-40202 injection or Placebo dosage form is solution for injection and route of administration is subcutaneous injection
BW-40202 injection or Placebo
BW-40202 injection or Placebo dosage form is solution for injection and route of administration is subcutaneous injection
BW-40202 injection or Placebo
BW-40202 injection or Placebo dosage form is solution for injection and route of administration is subcutaneous injection
BW-40202 injection or Placebo
BW-40202 injection or Placebo dosage form is solution for injection and route of administration is subcutaneous injection
Locations (1)
Argo Investigative Site
Perth, Western Australia, Australia